NEW YORK (GenomeWeb News) – Predictive Biosciences has closed a Series B financing that has brought in $21.75 million in funding, the Lexington, Mass.-based company said today.
 
Predictive Bio is developing biomarker-based assays for a variety of cancers, with an initial focus on bladder cancer. The firm also is looking into developing tests for breast, ovarian, prostate, and colorectal cancers.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers have sequenced the northern white rhinoceros to gauge whether it could be brought back from the edge of extinction, the New York Times reports.

Bavaria expands its forensic genetic analyses to include DNA phenotyping, raising discrimination concerns.

Tufts University researchers found a role for miRNA in transmitting stress between generations, the Economist reports.

In Science this week: gut microbiome influences liver cancer growth, spread; and more.